Clinical trials: Brain Cancer
Glioblastoma Multiforme
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
- Trial name
- NCT00892931
- Testing
- Azixa
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Myrexis Inc.
Glioblastoma Multiforme, Anaplastic Astrocytoma
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
In this study an investigational replication-defective, recombinant adenovirus expressing the interferon-beta gene (BG00001) will be directly injected into tumors, in patients with recurrent Grade III and Grade IV Gliomas, in…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
- Trial name
- NCT00031083
- Testing
- Interferon-beta
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Biogen
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Metastases, Neoplasm, Carcinoma, Non-Small-Cell Lung
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
Brain metastases from solid tumors are diagnosed in more than 300,000 patients annually. Nonsmall cell lung cancer accounts for the majority of CNS mets.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms
- Trial name
- NCT00034697
- Testing
- temozolomide
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
This is the first time in patient study to assess the safety, tolerability and preliminary efficacy of AZD3759 in patients with advanced Non Small Cell Lung Cancer (NSCLC) In this study, patients with Leptomeningeal Metastasis…
- Trial name
- BLOOM (NCT02228369)
- Testing
- AZD3759, AZD9291
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
HER2-negative Breast Cancer Patients With Brain Metastases
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases.
- Trial name
- NCT06764940
- Testing
- Utidelone, Utidelone in combination with capecitabine
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biostar Pharma, Inc.
Glioblastoma
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.
- Trial name
- NCT02014844
- Testing
- 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- ImmunityBio, Inc.
Glioma, Astrocytoma
Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
This clinical trial will study the safety and effectiveness of an engineered herpes virus, G207, administered directly into the brain of patients with recurrent brain cancer.
- Conditions
- Glioma, Astrocytoma, Glioblastoma
- Trial name
- NCT00028158
- Testing
- G207, an oncolytic virus
- Volunteers
- 65 people
- Sponsor
- MediGene
Meningioma, Tumor, Brain
MiDura-Study (Neuro-Patch in Duraplasty)
The aim of this study is to collect systematically and proactively data regarding the performance of Neuro-Patch, like complications and handling, under daily clinical practice when used as intended by the manufacturer
- Conditions
- Meningioma, Tumor, Brain, Chiari Malformation, Vascular Malformation
- Trial name
- MiDura (NCT04189172)
- Where
- 4 sites in France, Germany
- Volunteers
- 328 people
- Sponsor
- Aesculap AG
Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00562419
- Testing
- CT-322, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
Brain and Central Nervous System Tumors
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788 together with everolimus may kill more tumor cells.
- Trial name
- NCT00107237
- Testing
- AEE788, everolimus
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Advanced Solid Tumors, HER2-positive Breast Cancer
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without…
- Trial name
- NCT05593094
- Testing
- ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
- Trial name
- NCT07326566
- Testing
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Where
- 35 sites in United States
- Volunteers
- 162 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor.
- Conditions
- Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion
- Trial name
- RESCUE (NCT05307328)
- Testing
- SPI-62
- Where
- 12 sites in United States, Bulgaria and 1 more
- Volunteers
- 26 people
- Sponsor
- Sparrow Pharmaceuticals
Angiokeratomas, Chronic Kidney Disease
Biomarker for Patients With Fabry Disease (BioFabry)
Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood
- Conditions
- Angiokeratomas, Chronic Kidney Disease, Ocular Abnormalities, Hearing Loss
- Trial name
- BioFabry (NCT02778295)
- Where
- 3 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Recurrent Gliomas
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
This study will evaluate the safety and effectiveness of Enzastaurin, an experimental drug that may prevent the growth of tumor vessels, in combination with Carboplatin, for patients who have a glioma, a type of brain tumor.
- Trial name
- NCT01445119
- Testing
- Enzastaurin (LY317615), Carboplatin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Eli Lilly and Company
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
ONC201 in Pediatric H3 K27M Gliomas
This was a Phase 1, open label, multicenter, 8-arm, dose escalation study of dordaviprone (ONC201) in pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent/refractory H3 K27M-mutant…
- Trial name
- NCT03416530
- Testing
- Dordaviprone (ONC201)
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
Stroke, Meningioma
Robot-Assisted Neurovascular Intervention
Patients scheduled for neurovascular interventions may be eligible to have their procedure done robotically.
- Conditions
- Stroke, Meningioma, Neurovascular Disorder
- Trial name
- NCT06752096
- Testing
- cerebral angiography, arterial embolization, thrombectomy, Cerebral angiogram using robotic device, Meningioma embolization using robotic device.
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Navigantis Inc.
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals